Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth

Results Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage pointNet profit amounted to RMB148.6 million, increased by 3.1% YoYAdjusted non-IFRS net profit reached RMB183.5 million, increased by 9.1% YoYSHANGHAI, Aug. 28, 2025 /PRNewswire/ -- On August 28, 2025, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that the Gro ...